Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurelius Omlin

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
JCO Precision Oncology|November 4, 2022
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and PertuzumabStefanie Fischer, Thorsten O Götze, Aurelius Omlin, et al.
Journal of Translational Medicine|January 9, 2013
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion proteinJulien Laurent, Cedric Touvrey, Silke Gillessen, et al.
Investigational New Drugs|April 29, 2014
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II studyYohann Loriot, Karim Fizazi, Robert J Jones, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
Praxis|September 20, 2018
[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]Aurelius Omlin, Martin Spahn, Jörg Beyer, et al.
European Urology Open Science|May 15, 2023
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice ExperimentDominik Menges, Michela C Piatti, Aurelius Omlin, et al.
European Urology Focus|July 30, 2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional SurveyDavid Lorente, Praful Ravi, Niven Mehra, et al.
Science Translational Medicine|September 19, 2014
Tumor clone dynamics in lethal prostate cancerSuzanne Carreira, Alessandro Romanel, Jane Goodall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2023
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate CancerAurelius Omlin, Richard Cathomas, Gunhild von Amsberg, et al.
Swiss Medical Weekly|September 8, 2021
Swiss germ-cell cancer consensus recommendationsJörg Beyer, Dominik Berthold, Peter-Karl Bode, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
JCO Precision Oncology|November 4, 2022
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and PertuzumabStefanie Fischer, Thorsten O Götze, Aurelius Omlin, et al.
Journal of Translational Medicine|January 9, 2013
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion proteinJulien Laurent, Cedric Touvrey, Silke Gillessen, et al.
Investigational New Drugs|April 29, 2014
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II studyYohann Loriot, Karim Fizazi, Robert J Jones, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
Praxis|September 20, 2018
[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]Aurelius Omlin, Martin Spahn, Jörg Beyer, et al.
European Urology Open Science|May 15, 2023
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice ExperimentDominik Menges, Michela C Piatti, Aurelius Omlin, et al.
European Urology Focus|July 30, 2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional SurveyDavid Lorente, Praful Ravi, Niven Mehra, et al.
Science Translational Medicine|September 19, 2014
Tumor clone dynamics in lethal prostate cancerSuzanne Carreira, Alessandro Romanel, Jane Goodall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2023
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate CancerAurelius Omlin, Richard Cathomas, Gunhild von Amsberg, et al.
Swiss Medical Weekly|September 8, 2021
Swiss germ-cell cancer consensus recommendationsJörg Beyer, Dominik Berthold, Peter-Karl Bode, et al.
Pageof 10